Every peptide. Every trigger. Full transparency.

Sermorelin

GHRH(1-29) analog. Stimulates endogenous, pulsatile growth-hormone release from the anterior pituitary.

• →Restoration of physiologic GH/IGF-1 rhythm
• →Improved sleep architecture (slow-wave)
• →Lean body mass support

• →IGF-1 below 150 ng/mL
  Low IGF-1 suggests reduced GH pulse amplitude.

Ipamorelin

Selective ghrelin/GHS-R1a agonist. Triggers GH release without significant cortisol or prolactin elevation.

• →Recovery support
• →Sleep depth
• →Body-composition adjunct

• →IGF-1 below 150 ng/mL
  Suboptimal GH axis output.

CJC-1295 (no DAC)

GHRH analog with extended half-life vs sermorelin. Frequently paired with ipamorelin for additive pulse amplitude.

• →Lean mass support
• →Recovery
• →Sleep quality

• →IGF-1 below 150 ng/mL
  Reduced GH secretory output.

Tesamorelin

Stabilized GHRH analog with documented reduction of visceral adipose tissue and improvement in lipid profile.

• →Visceral fat reduction (~15–20% in trials)
• →Improved triglycerides
• →Possible cognitive benefit in HIV cohorts

• →Triglycerides above 150 mg/dL
  Elevated triglycerides + visceral adiposity pattern.
• →Fasting Insulin above 8 µIU/mL
  Insulin-resistant phenotype.

Hexarelin

Potent GHS-R1a agonist with additional cardioprotective signaling via CD36.

• →Strong GH pulse
• →Investigational cardioprotection

• →IGF-1 below 130 ng/mL
  Markedly suppressed GH axis.

Semaglutide

GLP-1 receptor agonist. Slows gastric emptying, enhances glucose-dependent insulin secretion, reduces appetite.

• →Average 15% body-weight reduction (STEP trials)
• →HbA1c reduction ~1.5%
• →MACE reduction (SUSTAIN-6)

• →HbA1c above 5.7 %
  Prediabetic glycemic pattern.
• →Fasting Insulin above 10 µIU/mL
  Insulin resistance.

Tirzepatide

Dual GIP/GLP-1 receptor agonist. Greater weight-loss efficacy than mono-agonists.

• →~20–22% body-weight reduction (SURMOUNT-1)
• →Superior glycemic control vs semaglutide (SURPASS-2)

• →HbA1c above 5.7 %
  Prediabetic glycemic pattern.
• →HOMA-IR above 2 index
  Insulin resistance.

AOD-9604

Synthetic fragment (hGH 176–191) that mimics GH lipolytic activity without affecting IGF-1 or glucose.

• →Targeted lipolysis
• →No GH-axis suppression
• →Minimal cardiovascular effect

• →Triglycerides above 130 mg/dL
  Adiposity-driven lipid pattern.

5-Amino-1MQ

Small-molecule NNMT inhibitor. Restores intracellular SAM and NAD+, promoting adipocyte energy expenditure.

• →Improved metabolic flexibility (preclinical)
• →Adipocyte lipolysis
• →Potential muscle preservation

• →HOMA-IR above 2 index
  Insulin resistance.

BPC-157

Pentadecapeptide derived from gastric juice. Promotes angiogenesis (VEGFR-2), tendon-to-bone healing, gut mucosal repair.

• →Soft-tissue and tendon repair
• →Gut lining integrity
• →Reduced local inflammation

• →hs-CRP above 1.5 mg/L
  Elevated systemic inflammation.

TB-500 (Thymosin β-4 fragment)

Synthetic 17-aa fragment of Tβ4. Modulates actin polymerization, supports angiogenesis and cell migration.

• →Tendon and muscle recovery
• →Endothelial repair
• →Possible hair regrowth signaling

• →hs-CRP above 2 mg/L
  Chronic inflammatory load.

GHK-Cu

Copper-binding tripeptide (glycyl-histidyl-lysine). Modulates >4,000 genes toward 'young' expression profiles.

• →Skin remodeling and collagen synthesis
• →Wound healing
• →Topical hair-follicle stimulation

KPV (α-MSH 11-13)

Anti-inflammatory tripeptide derived from α-MSH. Suppresses NF-κB-driven cytokine release in gut mucosa.

• →Investigational IBD support
• →Skin inflammation modulation

• →hs-CRP above 2 mg/L
  Gut/systemic inflammation.

LL-37

Endogenous human cathelicidin. Broad antimicrobial activity and immune modulation.

• →Investigational chronic infection support
• →Innate immunity tuning

• →Vitamin D (25-OH) below 30 ng/mL
  Vitamin D drives endogenous LL-37 expression.

MOTS-c

Mitochondrial-derived 16-aa peptide. Activates AMPK, improves insulin sensitivity, and supports mitochondrial biogenesis.

• →Improved insulin sensitivity (preclinical)
• →Exercise-mimetic effects
• →Metabolic flexibility

• →HOMA-IR above 1.8 index
  Insulin resistance.
• →HbA1c above 5.5 %
  Glycemic drift.

SS-31 (Elamipretide)

Cardiolipin-binding tetrapeptide that stabilizes the inner mitochondrial membrane and restores ATP production.

• →Mitochondrial efficiency
• →Investigational in primary mitochondrial myopathy and heart failure

• →Homocysteine above 9 µmol/L
  Methylation/mitochondrial strain.

NAD+ / NR / NMN

Replenishes cellular NAD+ pool — cofactor for sirtuins, PARPs, and mitochondrial energy metabolism.

• →Mitochondrial energy support
• →Sirtuin activation
• →Subjective cognitive clarity

• →Homocysteine above 9 µmol/L
  Methylation strain.

Epitalon

Synthetic pineal tetrapeptide (Ala-Glu-Asp-Gly). Animal data suggest telomerase upregulation and circadian normalization.

• →Subjective sleep quality
• →Circadian rhythm support

• →Cortisol (AM) above 18 µg/dL
  Dysregulated cortisol / poor sleep.

Humanin

Mitochondrial-derived 24-aa peptide with cytoprotective and metabolic signaling activity.

• →Cytoprotection (preclinical)
• →Investigational neuroprotection

Selank

Synthetic tuftsin analog with anxiolytic and BDNF-modulating activity.

• →Reduced anxiety scores in Russian trials
• →Focus and stress resilience (subjective)

• →Cortisol (AM) above 18 µg/dL
  Chronic HPA-axis activation.

Semax

Synthetic ACTH(4-10) fragment. Modulates BDNF, NGF, and dopaminergic tone.

• →Cognitive endurance
• →Investigational stroke recovery

Cerebrolysin

Porcine-derived neuropeptide preparation with neurotrophic activity (CREB/BDNF).

• →Adjunct in vascular dementia and stroke recovery

Dihexa

Hexapeptide angiotensin IV analog. Potent HGF/c-Met activator promoting synaptogenesis.

• →Investigational cognitive enhancement
• →Preclinical Alzheimer models

PT-141 (Bremelanotide)

Melanocortin-4 receptor agonist. Centrally mediated sexual arousal pathway.

• →Treatment of HSDD in premenopausal women
• →Investigational use in men with ED unresponsive to PDE5i

DSIP (Delta Sleep-Inducing Peptide)

Endogenous nonapeptide with proposed sleep-modulating, stress-buffering effects.

• →Subjective sleep quality
• →Stress modulation

• →Cortisol (AM) above 18 µg/dL
  Dysregulated cortisol.

Thymosin α-1

28-aa thymic peptide. Promotes T-cell maturation and Th1 polarization.

• →Adjunct in chronic hepatitis B/C
• →Immune support in immunosenescence
• →Investigational in sepsis

• →hs-CRP above 2 mg/L
  Inflammatory / immune dysregulation.

Larazotide

Zonulin antagonist. Tightens intestinal epithelial junctions, reducing gut permeability.

• →Investigational celiac disease adjunct
• →Leaky-gut research